Grants8

Grant Information	Key Details	Eligibility & Funding
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) PAR-25-353 Programme: National Institute of Mental Health (NIMH)	Grant Purpose and Target This grant, PAR-25-353, aims to accelerate innovative drug and device discovery and development for mental disorders. Its core objective is to advance preclinical development, early-stage human studies, and proof-of-concept (PoC) testing of new, rationally-based candidate agents or devices to treat mental illnesses. The grant explicitly targets academic institutions, the biotechnology industry, the biomedical device industry, and the pharmaceutical industry. It encourages the formation of multidisciplinary teams and public-private partnerships. There are no specific organizational size limits mentioned, but the nature of the research suggests medium to large research-capable entities. It is a SECTOR-SPECIFIC grant, focusing primarily on healthcare, pharmaceuticals, and biotechnology related to mental health. The geographic scope is strictly limited to organizations based in the United States. Foreign organizations are not eligible to apply, though foreign components within U.S. applications are allowed. Key filtering criteria for initial screening include being a U.S.-based entity involved in drug or device discovery/development for mental disorders, with an emphasis on novel interventions (not just analogs of existing treatments) and a willingness to engage in multidisciplinary collaborative research up to early human clinical trial phases. This grant is a recurring opportunity, a reissue of a previous program (PAR-22-144), with multiple application due dates occurring annually until October 2027, indicating an ongoing program context.	Funding Up to None USD Deadline Oct. 25, 2027, 5 p.m.	Details
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) PAR-25-268 Programme: National Institutes of Health (NIH)	This grant, PAR-25-268, supports investigator-initiated, fully remotely delivered and conducted clinical trials designed to assess the efficacy or effectiveness of complementary and integrative health interventions. The core objective is to build a rigorous evidence base for these approaches, often utilizing mHealth tools or technologies. It targets a broad range of US-based organizations including higher education institutions, various types of nonprofits, for-profit organizations (including small businesses), and federal/local government entities. The grant is SECTOR-SPECIFIC, focusing on healthcare research, particularly complementary and integrative health interventions. The geographic scope for applicant organizations is limited to the United States. While the trials must be fully remote, participants are expected to be geographically distributed across the US, and potentially Canada (trials conducted outside the US or Canada are not responsive). A key filtering criterion is the absolute requirement for a clinical trial that involves no in-person contact between research staff and study participants. This is a recurring grant opportunity, reissued from a previous announcement, with multiple application submission windows available until its expiration date in November 2026.	Funding Up to None USD Deadline Oct. 20, 2026, 10 p.m.	Details
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) PAR-25-067 Programme: National Institutes of Health (NIH) - National Institute of Mental Health (NIMH) Research Project Grant	This grant, the 'Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional),' from the National Institute of Mental Health (NIMH), aims to fund research that explores the connection between social disconnection (like isolation and loneliness) and suicidal thoughts and behaviors in older adults. The main goal is to identify the underlying neurobiological, behavioral, and environmental mechanisms that contribute to this risk or offer protection against it. This information is intended to help develop better prevention and intervention strategies. This is a SECTOR-SPECIFIC grant, focusing primarily on Mental Health and Public Health Research related to aging. It targets research organizations capable of conducting rigorous scientific studies. The geographic scope includes organizations within the United States and international (non-U.S.) entities. This is a recurring funding opportunity, building upon previous announcements.	Funding Up to None USD Deadline June 5, 2026, 5 p.m.	Details
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia PAR-25-065 Programme: NIH Research Project Grant	This grant aims to fund research that uncovers the underlying biological, behavioral, and social mechanisms of neuropsychiatric symptoms (NPS) in individuals with Alzheimer's disease (AD) or related dementias (ADRD), with the ultimate goal of developing new treatments. It primarily targets research organizations (such as higher education institutions, nonprofits, for-profit entities including small businesses, and government agencies) capable of conducting advanced biomedical, behavioral, and social sciences research. No specific organizational size is mandated beyond broad categories. This is a SECTOR-SPECIFIC grant focused on health and medical research, particularly neuroscience, aging, and mental health related to AD/ADRD. The geographic scope is global, with U.S. and non-U.S. entities being eligible. Key filtering criteria include a focus on mechanistic research in AD/ADRD-related NPS, the use of the R01 research project grant mechanism (typically not for early-stage ideas), and a requirement for comprehensive data sharing. This is a recurring opportunity, being a reissue of a previous announcement, with multiple submission deadlines until September 2026.	Funding Up to None USD Deadline June 5, 2026, 10 p.m.	Details
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) PAR-25-254 Programme: National Institutes of Health (NIH) - National Cancer Institute (NCI) Research Project Grant (R01)	This grant opportunity, PAR-25-254, is seeking mechanistic research to understand how and why `expectancy effects` occur in the context of cancer symptom management. The core objective is to leverage these effects to improve cancer outcomes and reduce health disparities, particularly for populations historically underrepresented or excluded from biomedical and behavioral research. This is a SECTOR-SPECIFIC grant, focused on cancer research and behavioral science related to health outcomes. It targets a broad range of organizational types, including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities, both domestic (US) and international (non-U.S.). This is a recurring funding opportunity, reissued from a previous program, indicating ongoing commitment to this research area.	Funding Up to None USD Deadline Feb. 5, 2026, 5 p.m.	Details
NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required) PAR-25-343 Programme: National Institutes of Health (NIH)	This grant, a Cooperative Agreement (U01) from the National Institute on Deafness and Other Communication Disorders (NIDCD), aims to fund investigator-initiated clinical trials in communication disorders. The core objective is to identify and advance effective interventions for conditions related to hearing, balance, smell, taste, voice, speech, and language, ultimately moving them into standard clinical care. This is a SECTOR-SPECIFIC grant focusing on healthcare research. It targets a wide range of U.S.-based organizations capable of conducting rigorous clinical trials, especially those requiring FDA oversight, establishing formal efficacy, involving higher risks, or having annual direct costs of $700,000 or more. The grant is offered through multiple application cycles over several years, indicating a recurring program.	Funding Up to None USD Deadline Oct. 18, 2027, 5 p.m.	Details
NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) PAR-25-239 Programme: National Institute of Dental and Craniofacial Research (NIDCR)	This funding opportunity, PAR-25-239, aims to support investigator-initiated observational studies or biomarker validation studies. These studies must involve either the prospective (future) collection of data or biological samples (biospecimens), or the continued analysis of data/biospecimens from previous research funded by the National Institute of Dental and Craniofacial Research (NIDCR). This grant is SECTOR-SPECIFIC, focusing primarily on research related to dental, oral, and craniofacial health and diseases. The target recipients are diverse research organizations, including academic institutions, non-profits, various government entities, and even small businesses, located within the United States. Foreign organizations cannot directly apply, but foreign components (e.g., international collaborators) can be part of a U.S. organization's application. This is a recurring funding opportunity, being a reissue of a previous program. Its core objective is to generate high-quality data to improve health outcomes in its specific focus areas.	Funding Up to None USD Deadline May 7, 2026, 4 a.m.	Details
Medical Scientist Training Program (MSTP) (T32) PAR-24-128 Programme: Ruth L. Kirschstein National Research Service Award (NRSA)	This grant, the Medical Scientist Training Program (MSTP) (T32), aims to develop a pool of highly skilled clinician-scientist leaders in the United States. Its core objective is to support eligible domestic organizations in establishing and running dual-degree training programs (e.g., M.D./Ph.D.) to prepare individuals for careers in biomedical research and clinical medicine. The program focuses on training future leaders who can translate scientific advances into improved human health, with particular emphasis on optimizing training efficiency, fostering persistence in research careers, and enhancing the clinician-scientist workforce. This grant is SECTOR-SPECIFIC, targeting the healthcare and biomedical research sectors. The primary target recipients are U.S. domestic organizations capable of hosting robust, integrated clinical and graduate research training programs. The grant supports institutions that can recruit and train predoctoral students pursuing dual clinical and research doctorate degrees. While the grant does not directly fund independent clinical trials led by trainees, it encourages research experience in mentor-led clinical trials. Key filtering criteria: Must be a U.S. organization, capable of running a dual-degree (clinical + Ph.D.) training program, and focused on biomedical research. The grant operates on multiple application cycles, indicating a recurring program within the broader Ruth L. Kirschstein National Research Service Award (NRSA) framework.	Funding Up to None USD Deadline Jan. 25, 2027, 5 p.m.	Details
Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) PA-23-317 Programme: National Institutes of Health (NIH)	This grant, PA-23-317, aims to provide financial support for the expansion of existing NIH-funded single project research grants and cooperative agreements. Its core objective is to allow current NIH award recipients to increase the scope of their ongoing projects. It is specifically designed for existing research organizations (not individuals or pre-revenue startups) that already hold a single project research grant or cooperative agreement from the National Institutes of Health. The grant is SECTOR-SPECIFIC, focusing exclusively on health and biomedical research under the broad mission of the NIH. The geographic scope is global, as both U.S. and non-U.S. entities are eligible to apply. A key filtering criterion for initial screening is that applicants must already possess an active NIH single project award and their application must be a direct response to a specific competitive revision Notice of Special Interest (NOSI). This is a recurring funding opportunity, building upon the previous PA-20-163.	Funding Up to None USD Deadline Nov. 24, 2026, 11:59 p.m.	Details
Sustainable business accommodation and business environment: support VLAIO-2822 Programme: VLAIO	This grant, `Duurzame bedrijfshuisvesting en bedrijfsomgeving: steun`, is an umbrella program by VLAIO and other Flemish governmental bodies. Its core objective is to stimulate greening and sustainable investments in business infrastructure and the broader business environment within Flanders, Belgium. It aims to support projects that enhance environmental sustainability, improve existing business sites, and contribute to climate action. The target recipients are diverse, including enterprises (SMEs and larger companies), organizations, individuals, public authorities, project developers, and various forms of partnerships/consortia. It is highly SECTOR-SPECIFIC, focusing on environmental protection, sustainable development, and green infrastructure within business and industrial contexts. The geographic scope is primarily Flanders, Belgium, with some specific sub-measures targeting particular provinces or cities like Oost-Vlaanderen, Antwerp, and Ghent. Key filtering criteria for initial screening are the project's location in Flanders and its direct relevance to environmental sustainability, greening, or sustainable infrastructure improvements at business sites. This is a collection of various support measures, some recurring annually, others with specific application windows, functioning as a continuous overview of available funding opportunities.	Funding Up to None EUR Deadline Dec. 31, 2027, midnight	Details
Thematic Call for Proposals: Space-based services for Digital Transformation and Sustainability in the Olympic and Paralympic Sport Sector AO/1-10494 Programme: ESA Business Applications Programme	This grant, a thematic call within ESA's standard AO/1-10494, aims to support the development of new space-based services. The core objective is to facilitate the digital transformation and enhance the sustainability of the sport sector, with a specific focus on the upcoming Olympic and Paralympic Games (e.g., Paris 2024, Milano Cortina 2026, and future editions). The target recipients are companies of any size, offering solutions that leverage space assets. This is a SECTOR-SPECIFIC grant, dedicated to the sport industry and its related events. Geographically, it targets companies residing in specific European Space Agency (ESA) Member States and associated countries. The key filtering criteria for initial screening are that applicants must be a company from an eligible country, proposing services that utilize space technology to address the needs of the Olympic and Paralympic Games. Applications can be submitted anytime until the final deadline, making it a recurring opportunity within a defined timeframe.	Funding Up to None EUR Deadline Dec. 31, 2025, 11:59 p.m.	Details
Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) PAR-23-084 Programme: National Institutes of Health (NIH) R01 Research Project Grant	The core objective of this grant is to support the implementation of investigator-initiated, hypothesis-driven clinical trials that require an extended project period of 6 or 7 years. These trials, which can be of any phase and include associated mechanistic studies, must align with the research missions and high-priority areas of the participating NIH Institutes/Centers (specifically the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute on Aging (NIA)). The grant aims to advance scientific knowledge and potentially change clinical practice by providing valuable information from long-term studies. It is a SECTOR-SPECIFIC grant focused on biomedical and health research. Target recipients include a broad range of U.S. and foreign organizations capable of conducting rigorous clinical trials. Key filtering criteria for initial screening are the strict requirement for an NIH-defined clinical trial, the justification for a 6- or 7-year duration, and readiness to implement the trial upon award. This is a recurring funding opportunity under the NIH R01 Research Project Grant program.	Funding Up to None USD Deadline Jan. 13, 2026, 5 p.m.	Details
Zorgsector steunmogelijkheden VLAIO-ZORG Programme: Vlaamse en Federale Overheid Steunmaatregelen voor de Zorgsector	This VLAIO overview serves as a comprehensive guide to various financial support opportunities (including subsidies, loans, guarantees, and premiums) available to organizations and professionals within the healthcare and welfare sector in Flanders, Belgium. Its core objective is to facilitate growth, innovation, sustainability, and operational efficiency across different types of care provisions. Target Audience & Scope Target Recipients: Ranges from individual general practitioners, medical group practices, and childcare providers to large-scale healthcare organizations, elderly care facilities, and institutions serving persons with disabilities. The page targets businesses, organizations, and independent professionals. Sector-Specific: This is SECTOR-SPECIFIC, focusing exclusively on the healthcare, welfare, and related social services sectors. Geographic Scope: Primarily covers Flanders, Belgium. However, some federal initiatives (e.g., certain RIZIV premiums) apply nationwide. Specific regional restrictions apply to certain investment subsidies (e.g., Vlabinvest for Flemish Rand and Leuven area). Key Filtering Criteria: Eligibility depends heavily on the specific type of organization, its activities within the care sector (e.g., general practice, childcare, elderly care, infrastructure development, digitalization, energy efficiency), and in some cases, its geographical location or a specific project phase (startup, investment, operational support). Grant Frequency: This VLAIO page is a recurring overview of ongoing and periodic support measures. The frequency of the individual underlying support instruments varies (e.g., annual applications, one-time calls, ongoing programs).	Funding Up to None EUR Deadline Dec. 31, 2025, midnight	Details
NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) PAR-24-100 Programme: National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Program	This grant encourages applications for the implementation of investigator-initiated, high-risk clinical trials, including associated mechanistic studies. The core objective is to advance understanding of human diseases and develop future therapeutic modalities related to infectious, immunologic, and allergic diseases. - Target Recipient: Organizations and institutions capable of conducting clinical trials, including universities, non-profits, for-profits (SME, enterprise), and various government entities. - Size: Not explicitly defined by employee count; capacity is determined by the ability to conduct complex clinical trials. - SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC. - Geographic Scope: Eligible to organizations globally (U.S. and non-U.S. entities). - Key Filtering Criteria: Must propose a single, high-risk clinical trial that aligns with NIAID's mission. Not for planning or non-high-risk trials. - Grant Frequency: Recurring, with multiple application deadlines through January 2027. This is a reissue of a previous funding opportunity.	Funding Up to None USD Deadline Jan. 13, 2027, 10 p.m.	Details
Call for Proposals (Non-Competitive) for Feasibility Study, Demonstration Project leveraging satellite technology to enhance the sustainability of sports and mass events 1-10494 Programme: ESA Business Applications	This grant invites proposals for Feasibility Studies and Demonstration Projects that use satellite technology to improve the sustainability of sports and mass events. Its core objective is to find innovative ways to reduce the environmental impact of large gatherings like sports championships, music festivals, and conferences. Target recipients are 'companies', which includes 'SME' and 'ENTERPRISE', as well as 'STARTUP' with promising business ideas. This is a SECTOR-SPECIFIC grant, focused on the global 'events industry', particularly 'sports' and 'mass events', with a strong emphasis on 'environmental sustainability' and 'space technology' applications. Geographic scope requires teams to be located in specific European countries. There are conditional eligibilities for Greece, Spain, and Canada. Key filtering criteria for initial screening include the explicit use of satellite technology and a direct contribution to sustainability in large-scale events. This is a recurring 'open call' with periodic reviews throughout 2025, rather than a one-time opportunity.	Funding Up to None EUR Deadline Oct. 10, 2025, 11:59 p.m.	Details
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) PAR-24-075 Programme: National Institutes of Health (NIH)	GRANT PURPOSE AND TARGET Single, clear statement of grant's core objective: To support innovative research projects that represent a significant change in research direction for Early Stage Investigators (ESIs), specifically projects for which no preliminary data exist. Explicit identification of target recipient type and size: Target recipients are Early Stage Investigators (ESIs), defined by NIH, affiliated with a wide range of organizations including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities. Organization size is not explicitly limited, but recipients must have the capacity to conduct research projects. SECTOR-SPECIFIC Geographic scope and any location requirements: Limited to organizations within the United States. Foreign organizations are not eligible to apply; however, foreign components (collaborations) of U.S. organizations are permitted. Key filtering criteria for initial grant screening: Applicant must be an Early Stage Investigator (ESI) as defined by NIH. Proposed research must represent a new research direction for the ESI (and all MPIs, if applicable). The application must not include preliminary data. Clinical trials are not allowed. Project must align with the mission of one or more participating NIH Institutes and Centers (ICs). Grant frequency and program context: This is a recurring grant opportunity (reissue of a previous PAR) with multiple application cycles through 2026.	Funding Up to None USD Deadline Sept. 28, 2026, 5 p.m.	Details
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-24-274 Programme: National Cancer Institute (NCI)	The 'NCI Research Specialist (Clinician Scientist) Award' (R50) aims to encourage stable research career opportunities for exceptional clinician scientists. These individuals are vital for sustaining the NCI-funded clinical trials enterprise by providing leadership in developing and implementing national clinical trials, and offering national service to NCI clinical trials networks. - Target Recipient Type: Clinician scientists with a clinical degree or relevant doctoral degree, actively practicing in oncology. - Target Recipient Size: Individual clinician scientists within academic medical centers or community centers that hold an NCORP award. - SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on healthcare, particularly oncology and cancer research. - Geographic Scope: United States. - Key Filtering Criteria: Must be a clinician scientist, actively practicing oncology, involved in NCI-funded cancer clinical trial-related activities, and not holding significant other NIH research project funding (R01, P01). - Grant Frequency and Program Context: This is a reissued funding opportunity (reissue of PAR-21-306) with annual application due dates, indicating a recurring program to provide sustained support for critical roles in cancer clinical trials.	Funding Up to None USD Deadline Nov. 4, 2025, 5 p.m.	Details
Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed) PAR-25-112 Programme: National Institutes of Health (NIH)	The 'Advancement and Innovation in Measurement of Language Development and Predictors' grant aims to encourage community-engaged research that broadens how we think about environmental factors supporting language development in children and focuses on creating new ways to measure children's language skills. The main goal is to build a collection of tools that are positive, respectful of different cultures and languages, and can be used widely to better understand language development and any difficulties. Target Recipient Type: Research institutions, non-profits, for-profit organizations, and government entities, including international organizations. Target Size: Not specified, but R01 grants typically support substantial projects. SECTOR-SPECIFIC: This grant is specifically focused on health and social sciences, particularly language development and measurement. Geographic Scope: United States and international (non-U.S.) entities are eligible. Key Filtering Criteria: Focus on novel language measurement, community engagement, and not clinical trials or interventions. Grant Frequency: Recurring with multiple application deadlines through September 2027. It's a reissue of a previous funding opportunity (PAR-24-243), indicating an ongoing program.	Funding Up to None USD Deadline June 5, 2027, 5 p.m.	Details
UNLP Scholarship and Fellowship Support Funding Opportunity UNLP Scholarship and Fellowship Programme: Nuclear Energy University Program (NEUP)	This grant aims to support the development of the nuclear energy workforce by providing financial assistance for educational pursuits. It targets undergraduate and graduate students pursuing studies in nuclear-related fields, primarily through their affiliated universities. - Target recipient type: Individual students (undergraduate and graduate) and the universities they attend. - Target recipient size: Individual students; universities are typically large organizations. - SECTOR-SPECIFIC: Nuclear Energy. - Geographic scope: United States. - Key filtering criteria: Student status (undergraduate/graduate), field of study (nuclear energy), university affiliation. - Grant frequency: Ongoing program, with this specific funding opportunity open for an extended period until October 14, 2030, and subject to amendments.	Funding Up to None USD Deadline Oct. 14, 2030, 11:59 p.m.	Details
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) PA-25-080 Programme: National Institutes of Health (NIH)	The NIH Research Conference Grant (R13) aims to support high-quality scientific conferences that are relevant to the National Institutes of Health's (NIH) mission and public health. This funding is designed for a broad range of domestic institutions and organizations, from universities and nonprofits to government entities and for-profit businesses, involved in health and scientific research. Core Objective: To foster the exchange of technical information, explore defined subjects, and stimulate advancements in public health and scientific knowledge through conferences. Target Recipient Type and Size: Domestic organizations of various sizes and structures, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities. Individuals are not eligible. Sector Designation: SECTOR-SPECIFIC (Health, Scientific Research). Geographic Scope: Applicant organizations must be based in the United States. While the applicant must be domestic, the conferences themselves can be international if hosted by an eligible U.S. organization. Key Filtering Criteria: Must be a U.S.-based organization; propose a scientific conference relevant to NIH's mission or public health; and must not involve clinical trials. Grant Frequency and Program Context: This is a recurring funding opportunity (Parent R13) with multiple annual application deadlines, reissued to align with evolving agency priorities. It is part of NIH's ongoing effort to support the scientific community.	Funding Up to None USD Deadline Aug. 12, 2027, 5 p.m.	Details

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

PAR-25-353

Programme: National Institute of Mental Health (NIMH)

Grant Purpose and Target This grant, PAR-25-353, aims to accelerate innovative drug and device discovery and development for mental disorders. Its core objective is to advance preclinical development, early-stage human studies, and proof-of-concept (PoC) testing of new, rationally-based candidate agents or devices to treat mental illnesses. The grant explicitly targets academic institutions, the biotechnology industry, the biomedical device industry, and the pharmaceutical industry. It encourages the formation of multidisciplinary teams and public-private partnerships. There are no specific organizational size limits mentioned, but the nature of the research suggests medium to large research-capable entities. It is a SECTOR-SPECIFIC grant, focusing primarily on healthcare, pharmaceuticals, and biotechnology related to mental health. The geographic scope is strictly limited to organizations based in the United States. Foreign organizations are not eligible to apply, though foreign components within U.S. applications are allowed. Key filtering criteria for initial screening include being a U.S.-based entity involved in drug or device discovery/development for mental disorders, with an emphasis on novel interventions (not just analogs of existing treatments) and a willingness to engage in multidisciplinary collaborative research up to early human clinical trial phases. This grant is a recurring opportunity, a reissue of a previous program (PAR-22-144), with multiple application due dates occurring annually until October 2027, indicating an ongoing program context.

Funding

Up to None USD

Deadline

Oct. 25, 2027, 5 p.m.

Details

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

PAR-25-268

Programme: National Institutes of Health (NIH)

This grant, PAR-25-268, supports investigator-initiated, fully remotely delivered and conducted clinical trials designed to assess the efficacy or effectiveness of complementary and integrative health interventions. The core objective is to build a rigorous evidence base for these approaches, often utilizing mHealth tools or technologies. It targets a broad range of US-based organizations including higher education institutions, various types of nonprofits, for-profit organizations (including small businesses), and federal/local government entities. The grant is SECTOR-SPECIFIC, focusing on healthcare research, particularly complementary and integrative health interventions. The geographic scope for applicant organizations is limited to the United States. While the trials must be fully remote, participants are expected to be geographically distributed across the US, and potentially Canada (trials conducted outside the US or Canada are not responsive). A key filtering criterion is the absolute requirement for a clinical trial that involves no in-person contact between research staff and study participants. This is a recurring grant opportunity, reissued from a previous announcement, with multiple application submission windows available until its expiration date in November 2026.

Funding

Up to None USD

Deadline

Oct. 20, 2026, 10 p.m.

Details

Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)

PAR-25-067

Programme: National Institutes of Health (NIH) - National Institute of Mental Health (NIMH) Research Project Grant

This grant, the 'Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional),' from the National Institute of Mental Health (NIMH), aims to fund research that explores the connection between social disconnection (like isolation and loneliness) and suicidal thoughts and behaviors in older adults. The main goal is to identify the underlying neurobiological, behavioral, and environmental mechanisms that contribute to this risk or offer protection against it. This information is intended to help develop better prevention and intervention strategies. This is a SECTOR-SPECIFIC grant, focusing primarily on Mental Health and Public Health Research related to aging. It targets research organizations capable of conducting rigorous scientific studies. The geographic scope includes organizations within the United States and international (non-U.S.) entities. This is a recurring funding opportunity, building upon previous announcements.

Funding

Up to None USD

Deadline

June 5, 2026, 5 p.m.

Details

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia

PAR-25-065

Programme: NIH Research Project Grant

This grant aims to fund research that uncovers the underlying biological, behavioral, and social mechanisms of neuropsychiatric symptoms (NPS) in individuals with Alzheimer's disease (AD) or related dementias (ADRD), with the ultimate goal of developing new treatments. It primarily targets research organizations (such as higher education institutions, nonprofits, for-profit entities including small businesses, and government agencies) capable of conducting advanced biomedical, behavioral, and social sciences research. No specific organizational size is mandated beyond broad categories. This is a SECTOR-SPECIFIC grant focused on health and medical research, particularly neuroscience, aging, and mental health related to AD/ADRD. The geographic scope is global, with U.S. and non-U.S. entities being eligible. Key filtering criteria include a focus on mechanistic research in AD/ADRD-related NPS, the use of the R01 research project grant mechanism (typically not for early-stage ideas), and a requirement for comprehensive data sharing. This is a recurring opportunity, being a reissue of a previous announcement, with multiple submission deadlines until September 2026.

Funding

Up to None USD

Deadline

June 5, 2026, 10 p.m.

Details

Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)

PAR-25-254

Programme: National Institutes of Health (NIH) - National Cancer Institute (NCI) Research Project Grant (R01)

This grant opportunity, PAR-25-254, is seeking mechanistic research to understand how and why expectancy effects occur in the context of cancer symptom management. The core objective is to leverage these effects to improve cancer outcomes and reduce health disparities, particularly for populations historically underrepresented or excluded from biomedical and behavioral research. This is a SECTOR-SPECIFIC grant, focused on cancer research and behavioral science related to health outcomes. It targets a broad range of organizational types, including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities, both domestic (US) and international (non-U.S.). This is a recurring funding opportunity, reissued from a previous program, indicating ongoing commitment to this research area.

Funding

Up to None USD

Deadline

Feb. 5, 2026, 5 p.m.

Details

NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

PAR-25-343

Programme: National Institutes of Health (NIH)

This grant, a Cooperative Agreement (U01) from the National Institute on Deafness and Other Communication Disorders (NIDCD), aims to fund investigator-initiated clinical trials in communication disorders. The core objective is to identify and advance effective interventions for conditions related to hearing, balance, smell, taste, voice, speech, and language, ultimately moving them into standard clinical care. This is a SECTOR-SPECIFIC grant focusing on healthcare research. It targets a wide range of U.S.-based organizations capable of conducting rigorous clinical trials, especially those requiring FDA oversight, establishing formal efficacy, involving higher risks, or having annual direct costs of $700,000 or more. The grant is offered through multiple application cycles over several years, indicating a recurring program.

Funding

Up to None USD

Deadline

Oct. 18, 2027, 5 p.m.

Details

NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

PAR-25-239

Programme: National Institute of Dental and Craniofacial Research (NIDCR)

This funding opportunity, PAR-25-239, aims to support investigator-initiated observational studies or biomarker validation studies. These studies must involve either the prospective (future) collection of data or biological samples (biospecimens), or the continued analysis of data/biospecimens from previous research funded by the National Institute of Dental and Craniofacial Research (NIDCR). This grant is SECTOR-SPECIFIC, focusing primarily on research related to dental, oral, and craniofacial health and diseases. The target recipients are diverse research organizations, including academic institutions, non-profits, various government entities, and even small businesses, located within the United States. Foreign organizations cannot directly apply, but foreign components (e.g., international collaborators) can be part of a U.S. organization's application. This is a recurring funding opportunity, being a reissue of a previous program. Its core objective is to generate high-quality data to improve health outcomes in its specific focus areas.

Funding

Up to None USD

Deadline

May 7, 2026, 4 a.m.

Details

Medical Scientist Training Program (MSTP) (T32)

PAR-24-128

Programme: Ruth L. Kirschstein National Research Service Award (NRSA)

This grant, the Medical Scientist Training Program (MSTP) (T32), aims to develop a pool of highly skilled clinician-scientist leaders in the United States. Its core objective is to support eligible domestic organizations in establishing and running dual-degree training programs (e.g., M.D./Ph.D.) to prepare individuals for careers in biomedical research and clinical medicine. The program focuses on training future leaders who can translate scientific advances into improved human health, with particular emphasis on optimizing training efficiency, fostering persistence in research careers, and enhancing the clinician-scientist workforce. This grant is SECTOR-SPECIFIC, targeting the healthcare and biomedical research sectors. The primary target recipients are U.S. domestic organizations capable of hosting robust, integrated clinical and graduate research training programs. The grant supports institutions that can recruit and train predoctoral students pursuing dual clinical and research doctorate degrees. While the grant does not directly fund independent clinical trials led by trainees, it encourages research experience in mentor-led clinical trials. Key filtering criteria: Must be a U.S. organization, capable of running a dual-degree (clinical + Ph.D.) training program, and focused on biomedical research. The grant operates on multiple application cycles, indicating a recurring program within the broader Ruth L. Kirschstein National Research Service Award (NRSA) framework.

Funding

Up to None USD

Deadline

Jan. 25, 2027, 5 p.m.

Details

Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)

PA-23-317

Programme: National Institutes of Health (NIH)

This grant, PA-23-317, aims to provide financial support for the expansion of existing NIH-funded single project research grants and cooperative agreements. Its core objective is to allow current NIH award recipients to increase the scope of their ongoing projects. It is specifically designed for existing research organizations (not individuals or pre-revenue startups) that already hold a single project research grant or cooperative agreement from the National Institutes of Health. The grant is SECTOR-SPECIFIC, focusing exclusively on health and biomedical research under the broad mission of the NIH. The geographic scope is global, as both U.S. and non-U.S. entities are eligible to apply. A key filtering criterion for initial screening is that applicants must already possess an active NIH single project award and their application must be a direct response to a specific competitive revision Notice of Special Interest (NOSI). This is a recurring funding opportunity, building upon the previous PA-20-163.

Funding

Up to None USD

Deadline

Nov. 24, 2026, 11:59 p.m.

Details

Sustainable business accommodation and business environment: support

VLAIO-2822

Programme: VLAIO

This grant, Duurzame bedrijfshuisvesting en bedrijfsomgeving: steun, is an umbrella program by VLAIO and other Flemish governmental bodies. Its core objective is to stimulate greening and sustainable investments in business infrastructure and the broader business environment within Flanders, Belgium. It aims to support projects that enhance environmental sustainability, improve existing business sites, and contribute to climate action. The target recipients are diverse, including enterprises (SMEs and larger companies), organizations, individuals, public authorities, project developers, and various forms of partnerships/consortia. It is highly SECTOR-SPECIFIC, focusing on environmental protection, sustainable development, and green infrastructure within business and industrial contexts. The geographic scope is primarily Flanders, Belgium, with some specific sub-measures targeting particular provinces or cities like Oost-Vlaanderen, Antwerp, and Ghent. Key filtering criteria for initial screening are the project's location in Flanders and its direct relevance to environmental sustainability, greening, or sustainable infrastructure improvements at business sites. This is a collection of various support measures, some recurring annually, others with specific application windows, functioning as a continuous overview of available funding opportunities.

Funding

Up to None EUR

Deadline

Dec. 31, 2027, midnight

Details

Thematic Call for Proposals: Space-based services for Digital Transformation and Sustainability in the Olympic and Paralympic Sport Sector

AO/1-10494

Programme: ESA Business Applications Programme

This grant, a thematic call within ESA's standard AO/1-10494, aims to support the development of new space-based services. The core objective is to facilitate the digital transformation and enhance the sustainability of the sport sector, with a specific focus on the upcoming Olympic and Paralympic Games (e.g., Paris 2024, Milano Cortina 2026, and future editions). The target recipients are companies of any size, offering solutions that leverage space assets. This is a SECTOR-SPECIFIC grant, dedicated to the sport industry and its related events. Geographically, it targets companies residing in specific European Space Agency (ESA) Member States and associated countries. The key filtering criteria for initial screening are that applicants must be a company from an eligible country, proposing services that utilize space technology to address the needs of the Olympic and Paralympic Games. Applications can be submitted anytime until the final deadline, making it a recurring opportunity within a defined timeframe.

Funding

Up to None EUR

Deadline

Dec. 31, 2025, 11:59 p.m.

Details

Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)

PAR-23-084

Programme: National Institutes of Health (NIH) R01 Research Project Grant

The core objective of this grant is to support the implementation of investigator-initiated, hypothesis-driven clinical trials that require an extended project period of 6 or 7 years. These trials, which can be of any phase and include associated mechanistic studies, must align with the research missions and high-priority areas of the participating NIH Institutes/Centers (specifically the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute on Aging (NIA)). The grant aims to advance scientific knowledge and potentially change clinical practice by providing valuable information from long-term studies. It is a SECTOR-SPECIFIC grant focused on biomedical and health research. Target recipients include a broad range of U.S. and foreign organizations capable of conducting rigorous clinical trials. Key filtering criteria for initial screening are the strict requirement for an NIH-defined clinical trial, the justification for a 6- or 7-year duration, and readiness to implement the trial upon award. This is a recurring funding opportunity under the NIH R01 Research Project Grant program.

Funding

Up to None USD

Deadline

Jan. 13, 2026, 5 p.m.

Details

Zorgsector steunmogelijkheden

VLAIO-ZORG

Programme: Vlaamse en Federale Overheid Steunmaatregelen voor de Zorgsector

This VLAIO overview serves as a comprehensive guide to various financial support opportunities (including subsidies, loans, guarantees, and premiums) available to organizations and professionals within the healthcare and welfare sector in Flanders, Belgium. Its core objective is to facilitate growth, innovation, sustainability, and operational efficiency across different types of care provisions. Target Audience & Scope

Target Recipients: Ranges from individual general practitioners, medical group practices, and childcare providers to large-scale healthcare organizations, elderly care facilities, and institutions serving persons with disabilities. The page targets businesses, organizations, and independent professionals.
Sector-Specific: This is SECTOR-SPECIFIC, focusing exclusively on the healthcare, welfare, and related social services sectors.
Geographic Scope: Primarily covers Flanders, Belgium. However, some federal initiatives (e.g., certain RIZIV premiums) apply nationwide. Specific regional restrictions apply to certain investment subsidies (e.g., Vlabinvest for Flemish Rand and Leuven area).
Key Filtering Criteria: Eligibility depends heavily on the specific type of organization, its activities within the care sector (e.g., general practice, childcare, elderly care, infrastructure development, digitalization, energy efficiency), and in some cases, its geographical location or a specific project phase (startup, investment, operational support).
Grant Frequency: This VLAIO page is a recurring overview of ongoing and periodic support measures. The frequency of the individual underlying support instruments varies (e.g., annual applications, one-time calls, ongoing programs).

Funding

Up to None EUR

Deadline

Dec. 31, 2025, midnight

Details

NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

PAR-24-100

Programme: National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Program

This grant encourages applications for the implementation of investigator-initiated, high-risk clinical trials, including associated mechanistic studies. The core objective is to advance understanding of human diseases and develop future therapeutic modalities related to infectious, immunologic, and allergic diseases. - Target Recipient: Organizations and institutions capable of conducting clinical trials, including universities, non-profits, for-profits (SME, enterprise), and various government entities. - Size: Not explicitly defined by employee count; capacity is determined by the ability to conduct complex clinical trials. - SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC. - Geographic Scope: Eligible to organizations globally (U.S. and non-U.S. entities). - Key Filtering Criteria: Must propose a single, high-risk clinical trial that aligns with NIAID's mission. Not for planning or non-high-risk trials. - Grant Frequency: Recurring, with multiple application deadlines through January 2027. This is a reissue of a previous funding opportunity.

Funding

Up to None USD

Deadline

Jan. 13, 2027, 10 p.m.

Details

Call for Proposals (Non-Competitive) for Feasibility Study, Demonstration Project leveraging satellite technology to enhance the sustainability of sports and mass events

1-10494

Programme: ESA Business Applications

This grant invites proposals for Feasibility Studies and Demonstration Projects that use satellite technology to improve the sustainability of sports and mass events.
Its core objective is to find innovative ways to reduce the environmental impact of large gatherings like sports championships, music festivals, and conferences.
Target recipients are 'companies', which includes 'SME' and 'ENTERPRISE', as well as 'STARTUP' with promising business ideas.
This is a SECTOR-SPECIFIC grant, focused on the global 'events industry', particularly 'sports' and 'mass events', with a strong emphasis on 'environmental sustainability' and 'space technology' applications.
Geographic scope requires teams to be located in specific European countries. There are conditional eligibilities for Greece, Spain, and Canada.
Key filtering criteria for initial screening include the explicit use of satellite technology and a direct contribution to sustainability in large-scale events.
This is a recurring 'open call' with periodic reviews throughout 2025, rather than a one-time opportunity.

Funding

Up to None EUR

Deadline

Oct. 10, 2025, 11:59 p.m.

Details

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)

PAR-24-075

Programme: National Institutes of Health (NIH)

GRANT PURPOSE AND TARGET

Single, clear statement of grant's core objective:
To support innovative research projects that represent a significant change in research direction for Early Stage Investigators (ESIs), specifically projects for which no preliminary data exist.
Explicit identification of target recipient type and size:
Target recipients are Early Stage Investigators (ESIs), defined by NIH, affiliated with a wide range of organizations including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities.
Organization size is not explicitly limited, but recipients must have the capacity to conduct research projects.
SECTOR-SPECIFIC
Geographic scope and any location requirements:
Limited to organizations within the United States.
Foreign organizations are not eligible to apply; however, foreign components (collaborations) of U.S. organizations are permitted.
Key filtering criteria for initial grant screening:
Applicant must be an Early Stage Investigator (ESI) as defined by NIH.
Proposed research must represent a new research direction for the ESI (and all MPIs, if applicable).
The application must not include preliminary data.
Clinical trials are not allowed.
Project must align with the mission of one or more participating NIH Institutes and Centers (ICs).
Grant frequency and program context:
This is a recurring grant opportunity (reissue of a previous PAR) with multiple application cycles through 2026.

Funding

Up to None USD

Deadline

Sept. 28, 2026, 5 p.m.

Details

NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

PAR-24-274

Programme: National Cancer Institute (NCI)

The 'NCI Research Specialist (Clinician Scientist) Award' (R50) aims to encourage stable research career opportunities for exceptional clinician scientists. These individuals are vital for sustaining the NCI-funded clinical trials enterprise by providing leadership in developing and implementing national clinical trials, and offering national service to NCI clinical trials networks. - Target Recipient Type: Clinician scientists with a clinical degree or relevant doctoral degree, actively practicing in oncology. - Target Recipient Size: Individual clinician scientists within academic medical centers or community centers that hold an NCORP award. - SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on healthcare, particularly oncology and cancer research. - Geographic Scope: United States. - Key Filtering Criteria: Must be a clinician scientist, actively practicing oncology, involved in NCI-funded cancer clinical trial-related activities, and not holding significant other NIH research project funding (R01, P01). - Grant Frequency and Program Context: This is a reissued funding opportunity (reissue of PAR-21-306) with annual application due dates, indicating a recurring program to provide sustained support for critical roles in cancer clinical trials.

Funding

Up to None USD

Deadline

Nov. 4, 2025, 5 p.m.

Details

Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)

PAR-25-112

Programme: National Institutes of Health (NIH)

The 'Advancement and Innovation in Measurement of Language Development and Predictors' grant aims to encourage community-engaged research that broadens how we think about environmental factors supporting language development in children and focuses on creating new ways to measure children's language skills. The main goal is to build a collection of tools that are positive, respectful of different cultures and languages, and can be used widely to better understand language development and any difficulties.

Target Recipient Type: Research institutions, non-profits, for-profit organizations, and government entities, including international organizations.
Target Size: Not specified, but R01 grants typically support substantial projects.
SECTOR-SPECIFIC: This grant is specifically focused on health and social sciences, particularly language development and measurement.
Geographic Scope: United States and international (non-U.S.) entities are eligible.
Key Filtering Criteria: Focus on novel language measurement, community engagement, and not clinical trials or interventions.
Grant Frequency: Recurring with multiple application deadlines through September 2027. It's a reissue of a previous funding opportunity (PAR-24-243), indicating an ongoing program.

Funding

Up to None USD

Deadline

June 5, 2027, 5 p.m.

Details

UNLP Scholarship and Fellowship Support Funding Opportunity

UNLP Scholarship and Fellowship

Programme: Nuclear Energy University Program (NEUP)

This grant aims to support the development of the nuclear energy workforce by providing financial assistance for educational pursuits. It targets undergraduate and graduate students pursuing studies in nuclear-related fields, primarily through their affiliated universities. - Target recipient type: Individual students (undergraduate and graduate) and the universities they attend. - Target recipient size: Individual students; universities are typically large organizations. - SECTOR-SPECIFIC: Nuclear Energy. - Geographic scope: United States. - Key filtering criteria: Student status (undergraduate/graduate), field of study (nuclear energy), university affiliation. - Grant frequency: Ongoing program, with this specific funding opportunity open for an extended period until October 14, 2030, and subject to amendments.

Funding

Up to None USD

Deadline

Oct. 14, 2030, 11:59 p.m.

Details

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

PA-25-080

Programme: National Institutes of Health (NIH)

The NIH Research Conference Grant (R13) aims to support high-quality scientific conferences that are relevant to the National Institutes of Health's (NIH) mission and public health. This funding is designed for a broad range of domestic institutions and organizations, from universities and nonprofits to government entities and for-profit businesses, involved in health and scientific research.

Core Objective: To foster the exchange of technical information, explore defined subjects, and stimulate advancements in public health and scientific knowledge through conferences.
Target Recipient Type and Size: Domestic organizations of various sizes and structures, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities. Individuals are not eligible.
Sector Designation: SECTOR-SPECIFIC (Health, Scientific Research).
Geographic Scope: Applicant organizations must be based in the United States. While the applicant must be domestic, the conferences themselves can be international if hosted by an eligible U.S. organization.
Key Filtering Criteria: Must be a U.S.-based organization; propose a scientific conference relevant to NIH's mission or public health; and must not involve clinical trials.
Grant Frequency and Program Context: This is a recurring funding opportunity (Parent R13) with multiple annual application deadlines, reissued to align with evolving agency priorities. It is part of NIH's ongoing effort to support the scientific community.

Funding

Up to None USD

Deadline

Aug. 12, 2027, 5 p.m.

Details

You can filter by below criteria

Grants